|Articles|January 12, 2022

Tufts CSDD Releases January/February 2022 Impact Report

Tufts CSDD has released the latest version of its bi-monthly Impact Report. In this January/February 2022 edition, the focus is on an issue that has plagued the pharmaceutical industry for years: the incidence of protocol deviations and amendments in clinical trials. While these hurdles are both at new highs across all phases, they have been steadily increasing since the start of the COVID-19 pandemic.

From the results a new Tufts CSDD analysis conducted in 2020, some of the highlights in the report are:

Actual timelines for protocols with three or more substantial amendments are nearly three weeks longer than planned treatment durations.
In a typical Phase III trial, 119 protocol deviations, on average, are implemented, involving approximately one-third of all patients participating in that trial.

The full report is available for purchase here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

© photon_photo - © photon_photo - stock.adobe.com

October 15th, 2026

Endpoints That Reflect What Patients Actually Value: Who Decides What Counts as Trial Success

Clinical trial endpoints define what success looks like, but patients and caregivers are rarely the ones setting that definition, and the gap between what trials measure and what patients actually value is showing up in post-approval evidence, regulatory submissions, and the design rooms where protocols are written.

October 15th, 2026

The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution

In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.

October 15th, 2026

ACT Brief: EHR-to-EDC Connectivity, FDA’s Rare Disease Framework, and Barriers to Oncology RWE

In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.

October 14th, 2026

FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations

A new white paper and public engagement process outline the FDA’s commitment to building fit-for-purpose evidentiary standards, stronger patient voice integration, and greater regulatory predictability across rare disease drug development and review.

© putilov_denis - © putilov_denis - stock.adobe.com

October 14th, 2026

Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection

Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.

October 14th, 2026

ACT Brief: Design Drivers of Trial Representation, eSource-to-EDC Data Automation, and Roche's ALK7 Obesity License

In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.

October 13th, 2026

IgniteData and RealTime Partner to Streamline Clinical Data Transfer From eSource to Sponsor Systems

The partnership gives RealTime's network of more than 3,000 research sites access to the Archer platform for direct, automated data transfer from eSource to any sponsor electronic data capture system or data destination.

October 13th, 2026

The Biggest Remaining Barriers to High-Quality RWE Across Oncology Data Platforms

In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, identify three persistent obstacles to consistent real-world evidence generation in oncology—inconsistent data capture, structural data limitations that modeling alone can't fix, and the need for earned generalizability through deliberate multi-site validation.

Tufts CSDD Releases January/February 2022 Impact Report

Related to this article

Trending on Applied Clinical Trials Online

Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection

FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations

The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution

ACT Brief: EHR-to-EDC Connectivity, FDA’s Rare Disease Framework, and Barriers to Oncology RWE

Endpoints That Reflect What Patients Actually Value: Who Decides What Counts as Trial Success